Phase II trials from 2022 to 2024 further confirmed the promising anti-tumor activity of combining apatinib with chemotherapy and PD-1 inhibitors in the second-line treatment of advanced GC (63, 83). This evidence concerns the gene PDCD1 and neoplasm.